Intensity Therapeutics’ stock has risen nearly 400% after its oncology candidate showed high overall survival (OS) and ...

Kids with a rare bone cancer called Ewing sarcoma might live longer if prescribed pazopanib, a drug that blocks blood supply ...

Globally, synovial sarcoma remains a rare but aggressive malignancy with a 5-year survival rate of 70% to 80% and a 10-year ...

Intensity Therapeutics (INTS), with a ~$13M market cap, closed up nearly 395% Thursday after publishing phase 1/2 results on ...

Intensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" or "the Company"), a late-stage clinical biotechnology company ...

Survival rates from small trial suggest that adding pazopanib to standard treatment for Ewing sarcoma in children may extend lives without adding severe toxicity.

Intensity Therapeutics shares plunged 31.9% after-hours following the publication of Phase 1/2 trial results for its cancer ...

Ewing sarcoma is one of the most common bone cancers seen in children, and if it spreads, it can be deadly. One study found ...

In patients with mostly undifferentiated pleomorphic sarcomas, 2-year DFS with the addition of preoperative and postoperative pembrolizumab (Keytruda) infusions reached 67%, as compared with 52% with ...

In a remarkable turn of events, Intensity Therapeutics (INTS) has seen its stock surge by 195% following the announcement of promising results from its Phase 1/2 IT-01 clinical trial. This study ...

Eftilagimod alfa and Keytruda with radiotherapy improved tumor hyalinization/fibrosis rates in resectable soft tissue sarcoma, surpassing the trial's primary endpoint. The combination therapy achieved ...